Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 2, 2018, Pages 322-328

  Matsuoka, Osamu ^a   Patel, Dhaval M ^b   Sasaki, Shin ^c   Oka, Hayato ^c   Sasaki, Toru ^c   Pietrobon, Patricia J ^b   Laot, Thelma ^d   Bouckenooghe, Alain ^e   Menezes, Josemund ^e   de Bruyn, Guy ^b  

^a TOCROM Clinic   (Japan)

^b SANOFI PASTEUR   (France)

^c Sanofi Pasteur Medical ^*  (Japan)

^d Sanofi Pasteur   (Philippines)

^e Sanofi Pasteur Clinical Development Department   (Singapore)

Author keywords

Clostridium difficile; immunogenicity; safety; vaccine

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; IMMUNOGLOBULIN G; PLACEBO; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE; BACTERIAL TOXIN; BACTERIUM ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; JAPANESE (CITIZEN); MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINE IMMUNOGENICITY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, BACTERIAL; ASIAN CONTINENTAL ANCESTRY GROUP; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROCONVERSION;

EID: 85037976207     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1395538     Document Type: Article

References (17)

1. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infectin in the United States. N Engl J Med. 2015;372(9):825–34. doi:10.1056/NEJMoa1408913.
2. Kyne L, Farrell FJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30(3):753–77, ix-x. doi:10.1016/S0889-8553(05)70209-0.
3. Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–99.
4. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ,; ECDIS Study Group. Clostridiumdifficile infection in Europe: a hospital-based survey. Lancet 2011;377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4.
5. Mori N, Yoshizawa S, Saga T, Ishii Y, Murakami H, Iwata M, Collins DA, Riley TV, Tateda K. Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan. J Infect Chemother. 2015;21(10):718–22. doi:10.1016/j.jiac.2015.06.009.
6. Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, Totsaku K. Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital. Clin Exp Gastroenterol. 2015;8:191–6.
7. Honda H, Yamazaki A, Sato Y, Erik Dubberke. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe. 2014;25:5–10. doi:10.1016/j.anaerobe.2013.10.004.
8. Yoshida J, Kikuchi T, Asano I, Ueno T. Clostridium difficile infection relationship to ward-monthly antimicrobial use density and days of treatment: a three-year study. Jpn J Infect Prev Control. 2016;31(2):92–9. doi:10.4058/jsei.31.92.
9. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–92.
10. Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. The burden of Clostridium difficile-associated disease following digestive tract surery in Japan. J Hosp Infect. 2012;82(3):175–80. doi:10.1016/j.jhin.2012.07.023.
11. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium diffcile toxoid vaccine. Vaccine. 2012;30(13):2245–9. doi:10.1016/j.vaccine.2012.01.065.
12. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30(29):4307–9. doi:10.1016/j.vaccine.2012.01.056.
13. de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine agrainst Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016;34(19):2170–8. doi:10.1016/j.vaccine.2016.03.028.
14. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine. 1998;17(8):857–72. doi:10.1002/(SICI)1097-0258(19980430)17:8%3c857::AID-SIM777%3e3.0.CO;2-E.
15. Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine. 2016;34(18):2082–91. doi:10.1016/j.vaccine.2016.03.010.
16. Bezay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine. 2016;34(23):2585–92. doi:10.1016/j.vaccine.2016.03.098.
17. Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6.